Paramount Clears Major Legal Hurdle for Warner Megadeal

The episode begins with reports on President Trump's decision to ban CNN, MS Now, Politico, and other media outlets from White House access. WSJ reporter Isabella Seminetti details the practical effects shortly after the announcement, including CNN reporter Betsy Klein being told her badge was deactivated and Politico’s editor-in-chief Jonathan Greenberger noting the Secret Service confiscated their reporter’s pass. MS Now’s Ekela Gardner also experienced badge issues. Trump defended his actions, claiming he was targeting 'fake news' and framing it as a matter of national security. The media outlets responded by asserting that they will not accept restrictions on their coverage and are thus filing a lawsuit against the administration, citing First Amendment rights and the need to cover the president. The episode recounts past disputes between the Trump administration and the press, particularly noting that similar conflicts date back to the Obama era, but this escalation appears more severe now with multiple outlets suspending coverage or challenging the ban in court.

The conversation then shifts to Paramount's settlement with state attorneys general, which effectively removes a significant obstacle to its planned $81 billion merger with Warner Bros. Discovery. WSJ Los Angeles Bureau Chief Ryan Fonder explains that the settlement aims to preserve jobs and increase domestic production, with Paramount agreeing to spend an additional $300 million annually in the U.S. and commit to releasing at least 30 movies annually from the combined entities. However, restrictions will prevent Paramount from bundling cable distribution negotiations with Warner Bros. This deal must be finalized soon to avoid a daily $7 million ticking fee starting October 1, with a potential court trial scheduled for March. The discussion emphasizes the substantial financial risk if the merger is delayed, including how extra days beyond October could cost billions.

Alex Janen reports on Novo Nordisk’s investor day in London, highlighting that despite unveiling new pipeline drugs intended to sustain growth, the company’s stock fell nearly 8%. Investors are concerned about Novo’s strategy post-2031, after its blockbuster weight-loss drug Ozempic faces patent expiry, and about achieving competitive advantages over Eli Lilly, which currently outperforms Novo in weight-loss efficacy. Novo announced some promising data for drugs like Cagri Sema but allocated no guidance beyond 2030, leaving questions about how it will replace lost sales. The episode underscores that while Novo has gained significant market share with oral medications, the market still expects it to deliver future blockbuster drugs, which it has yet to do.

The hosts note that U.S. stocks opened the week strongly, with the NASDAQ reaching its first record close since June, driven by gains in chipmakers and AI-related stocks. The S&P 500 and Dow also rose, and falling oil prices contributed to the positive mood. The decline in oil prices, specifically Brent crude falling to about $100 per barrel, helped lower global bond yields, with the 10-year Treasury yield dropping below 5%. This suggests optimism in the markets and potential easing in inflation concerns, supporting the positive stock performance at the start of the week.

The episode concludes with a report on OpenAI urging the U.S. government to establish global safety and security standards for artificial intelligence. They propose sharing threat information and evaluating self-improving AI systems with standardized measures. Meanwhile, President Trump has resisted regulation calls, stating that growth will not be stifled but that law enforcement can act if necessary. The episode also covers a major air traffic disruption caused by an equipment outage—stemmed from a fiber optic cut—affecting Newark, Philadelphia, and other airports, causing delays and diversions during the busy United Nations General Assembly week.